Menú Close

Artículos sobre Alzheimer's disease

Mostrando 41 - 60 de 340 artículos

Though this genetic form of Alzheimer’s only affects around 1% of the population, it provides useful information on how the disease progresses. Atthapon Raksthaput/ Shutterstock

Alzheimer’s: blood biomarker may help identify the disease ten years before symptoms start

Although autosomal dominant Alzheimer’s disease is very rare, studying it provides researchers with valuable information on how the disease progresses in general.
Many viruses interact with the olfactory system, and can damage other areas of the brain through it. Mohammed Haneefa Nizamudeen/iStock via Getty Images Plus

Vaccination to prevent dementia? New research suggests one way viral infections can accelerate neurodegeneration

Inflammation and damage to the olfactory system from shingles, COVID-19 and herpes infections may contribute to Alzheimer’s disease.
Alzheimer’s disease is an incapacitating, progressive brain disorder that affects the lives of more than 6.5 million Americans. PamelaJoeMcFarlane/E+ via Getty Images

What the FDA’s accelerated approval of a new Alzheimer’s drug could mean for those with the disease – 5 questions answered about lecanemab

In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
Lecanemab is an antibody that attaches to beta-amyloid proteins accumulated in the brain and allows the immune system to get rid of them. (Shutterstock)

Lecanemab: Experimental drug is a ray of hope for Alzheimer’s disease

An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.

Principales colaboradores

Más